Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

April 30, Top 20 Shareholders

200501_top20shareholders

Categories: News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard April 30, 2020

Related posts

January 31, Top 20 Shareholders
February 1, 2021

December 31, Top 20 Shareholders
January 4, 2021

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials
December 23, 2020

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
December 22, 2020

December 21, Epichem Awarded DNDi Extension
December 21, 2020

December 4, Issued Capital
December 4, 2020

Recent Articles

February 15, Canine Monepantel Phase IIb Lymphoma Trial Update
February 14, 2021
February 10, LUMC Covid-19 Research Update
February 10, 2021
January 31, Top 20 Shareholders
February 1, 2021
January 27, Appendix 4C and Quarterly Update
January 27, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

“We think products such as MPL will happily co-exist with vaccines,” $PAA Executive Chairman, Dr Roger Aston told @StockheadAU yesterday.

https://stockhead.com.au/health/so-covid-vaccines-are-here-what-now-for-all-those-biotechs-working-on-covid-19-drugs-or-tests/

Reply on Twitter 1364338373138161666 Retweet on Twitter 13643383731381616664 Like on Twitter 13643383731381616666 Twitter 1364338373138161666

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions